Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

    NEXT STORY
    Dr Kristi Kuper Joins DoseMe as Director of Clinical Pharmacy
    PREV STORY
    Global Syringes and Cannulas Market is Expected to Reach USD 2.23 Billion by 2025 : Fior Markets
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron to Evaluate Combination Therapy for Patients with Brain Cancer     

    BOSTON, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc., (Nasdaq:ZIOP) today announced a ...

    author_avatar
    NASDAQ Market News

    Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer

    BUFFALO, N.Y., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc., a global biopharmaceutical company dedicated ...

    author_avatar
    NASDAQ Market News

    Inventiva – New promising results on lanifibranor to be presented at The Liver Meeting® 2019

    author_avatar
    NASDAQ Market News